{
  "@context": "https://orbyd.app/schemas/dossier.v1.json",
  "ticker": "ACB",
  "name": "Aurora Cannabis Inc.",
  "url": "https://orbyd.app/dossiers/ACB/",
  "json_url": "https://orbyd.app/dossiers/ACB.json",
  "status": "DORMANT",
  "current_conviction": "LOW",
  "graded_conviction": null,
  "archetype": {
    "code": "a5",
    "n": 5
  },
  "current_thesis": "US-reschedule sentiment is spent for this name: the DEA Schedule-III hearing closed July 15 2026 with no ALJ timeline, and the economics accrue to US operators, not a Canadian LP. The Aug 5 Q1 FY2027 print is a guided transitional-year step-down. Debt-free international-medical grower, but broken structure near a $2.63 low — stand aside until it bases.",
  "invalidation_trigger": "A weekly close below $2.63 (a fresh 52-week low) confirms the breakdown extends and voids any basing/bounce probe; reinforced if the Aug 5 2026 Q1 print guides FY2027 revenue lower or pairs a dilutive raise, or the DEA ALJ read lands US-recreational-only with no Canadian-LP benefit.",
  "catalyst_date": "2026-08-05",
  "outcome": "OPEN",
  "outcome_date": null,
  "invalidation_fired": null,
  "themes": [
    "cannabis-reclassification"
  ],
  "tags": [],
  "sources": [],
  "notes": [
    "EARNINGS BLACKOUT: Q1/FY2027 print Aug 5 2026 pre-open (~8am ET webcast); by ~July 31 this is <3 trading days out - avoid fresh entries into the print. Street ~$54.9M revenue, a sequential decline from $61.8M Q4.",
    "Canadian LP - the US 280E / Schedule-III catalyst does NOT accrue to it; it only catches sector sentiment beta. Cleaner US reschedule plays are MSOs / MSOS ETF (GTBIF, CURLF, TCNNF).",
    "DEA Schedule-III hearing closed ~July 15 2026; post-hearing briefs due Aug 17; ALJ recommendation + administrator decision undated - no near-term regulatory catalyst. April 28 2026 downschedule covered state-medical + FDA products only (US-operator economics).",
    "Retail-squeeze characteristics (sub-$3, heavy-retail float, chronic dilution/reverse-split history) - keep sizing tight (<=1-2%) even on a probe.",
    "Price near 52-wk low ($2.63-$6.67 range) - do NOT average down; only re-engage on an event-driven 50-DMA reclaim on expanding volume.",
    "FY2027 guided 'transitional year': total net revenue toward FY2025 levels, adj EBITDA lower YoY, adj gross margin easing to mid-to-high 50s from 64%, on a ~30% Canadian medical reimbursement cut effective April 1 2026.",
    "AGM Aug 7 2026 (circular filed July 8) - watch for capital-authorization / share-issuance votes given dilution history.",
    "FY2026 fundamentals (reported June 11 2026): record medical net revenue $289M (+18% YoY), adj EBITDA +32% to $54M, international medical $177M (55% of revenue outside Canada), debt-free with $165M cash."
  ],
  "body_markdown": "## Current Thesis\nAurora is a debt-free Canadian licensed producer re-rating on an international-medical growth engine (Germany, Poland, Australia), but the day-to-day tape treats it as high-beta sentiment exposure to a US cannabis-reschedule trade whose economics never reach it. The June 29–July 15 2026 DEA Schedule-III hearing has closed with no ALJ recommendation timeline, removing the last live near-term sentiment driver. The next hard event is the August 5 2026 Q1 FY2027 print — a transitional-year binary the company has already guided toward a revenue step-down. The stock is pinned near a $2.63 52-week low with no higher-low base. This is a structural laggard into a spent catalyst; stand aside until it bases.\n\n## Bull Case\n- **International medical is compounding and high-margin.** FY2026 (reported June 11 2026): record global medical net revenue $289M (+18% YoY), adjusted EBITDA +32% to $54M, international medical revenue $177M — 55% of total revenue now sits outside Canada.\n- **Balance sheet is clean.** Aurora exited FY2026 debt-free with $165M cash (June 11 2026 report), so the near-term solvency and forced-dilution overhang dogging several MSO peers is off the table.\n- **German franchise is winning share.** Two proprietary cultivars ranked #1 and #3 by sales in Germany in the Q4/FY26 quarter (June 11 2026 call); the Leuna, Germany expansion completes in H1 FY2027 and is guided to double that site's annual flower output.\n- **Top-line beat on the last print.** Q4/FY26 revenue $61.842M vs $55.290M consensus at a 64% adjusted gross margin (June 11 2026).\n- **Sell-side still nominally constructive.** Consensus \"Buy,\" average price target ~$6.16 (stale) — a wide gap the tape would reprice if the international engine outruns the Canadian drag faster than guided.\n\n## Bear Case\n- **The live catalyst does not pay this ticker.** The April 28 2026 final order downscheduling state-medical and FDA-approved marijuana products to Schedule III — and the pending broad reschedule — are US-operator economics (GTBIF, CURLF, TCNNF, the MSOS ETF). A Canadian LP with no US THC operations only catches sentiment beta.\n- **The catalyst is now open-ended.** The DEA hearing closed ~July 15 2026, post-hearing briefs are due August 17, and the ALJ recommendation plus administrator decision carry no announced timeline — the near-term driver is gone, replaced by a multi-quarter rulemaking process.\n- **FY2027 is a guided step-down.** Management framed FY2027 as a transitional year: total net revenue declining toward FY2025 levels, adjusted EBITDA lower YoY, and adjusted gross margin easing to the mid-to-high 50s from 64%, driven by a ~30% cut to Canadian medical reimbursement effective April 1 2026.\n- **The August 5 print skews negative.** Street models roughly $54.9M revenue for Q1 FY2027, a sequential decline from the $61.8M Q4 run-rate — exactly the softening the transitional-year guide telegraphs.\n- **Broken structure, dilutive float.** A fresh $2.63 52-week low, ~59% below the $6.67 high, with the prior ~$3.07 shelf lost; a sub-$3 heavy-retail float with reverse-split and dilution history caps any sentiment pop.\n\n## Setup & Price Structure\n- Price is pinned near the $2.63 52-week low inside a $2.63–$6.67 range — roughly 59% off the high with no reclaim of prior support.\n- The ~$3.07 shelf cited in mid-June has been lost; price trades below its declining 50- and 200-DMA — declining-MA structure, not a base forming.\n- Market cap ~$165–169M against $165M of cash means the market is valuing the operating business at close to zero, which in a chronically dilutive float reads as a value trap more than a floor.\n- Any re-engagement needs an event-driven reclaim of the 50-DMA on expanding volume; absent that, expect low-dollar drift with retail-squeeze optionality only on a sector-wide sentiment spike.\n- Weakness here is not an averaging opportunity — a broken sub-low print offers no structural support to lean on.\n\n## Catalyst Calendar (next 30 days)\n\n- **2026-08-17 (confirmed):** Post-hearing briefs due in the DEA Schedule-III proceeding. A procedural milestone that carries no decision; the ALJ recommendation remains undated.\n- No FDA/PDUFA date or index event in the window. The next Canadian-LP-specific fundamental read is the August 5 print.\n\n## Elapsed catalysts\n\n- **2026-08-05 (confirmed):** Q1 FY2027 results, before US market open, 8:00am ET webcast. Street ~$54.9M revenue; first print under the transitional-year guide and the binary event of the window. *(passed 4d ago)*\n- **2026-08-07 (confirmed):** Virtual AGM; management information circular filed July 8 2026. Routine — watch specifically for any capital-authorization or share-issuance votes given the dilution history. *(passed 2d ago)*\n\n## What Would Change Our Mind\n- A weekly close reclaiming the 50-DMA on expanding volume that establishes a higher low above ~$2.63 — the first genuine evidence of a base rather than continued markdown.\n- An August 5 2026 print where international medical (Germany/Poland/Australia) revenue growth visibly offsets the Canadian reimbursement cut, holding consolidated revenue flat-to-up sequentially despite the guide.\n- A regulatory development that actually reaches a Canadian LP — EU/German recreational-access progress or a German medical-flower volume step-up — rather than a US-recreational headline that leaves ACB's economics untouched.\n- A clustered options build ahead of August 5 (call/put >2, rising IV) signalling positioning, versus the current dead tape.\n\n## Correlation Notes\n- Trades as high-beta sector sentiment against the US MSO complex (MSOS ETF, GTBIF, CURLF, TCNNF), but with a structural laggard discount because the reschedule economics accrue to US operators, not a Canadian LP. Relative weakness was flagged June 4 2026 when MSOS broke out +7.6% to $5.10 while ACB stayed pinned at its low.\n- Correlated to DEA-proceeding headline risk and to broad small-cap/retail risk appetite; a low-dollar, heavy-retail float amplifies moves in both directions.\n- The fundamental story ties to German/EU medical-cannabis policy and EUR/CAD via $177M FY2026 international-medical revenue — a slower-moving driver than the US-sentiment beta that sets the daily tape.\n- Idiosyncratic risk dominates index correlation: Canadian medical reimbursement policy (the ~30% cut effective April 1 2026) and Aurora-specific dilution history are the swing variables.",
  "first_seen": "2026-04-23",
  "last_analyzed": "2026-07-26T11:17:57+00:00",
  "last_synthesized": "2026-07-26",
  "last_update_source": "watchlist_research",
  "license": "Content © orbyd. Cite the canonical URL."
}